医学
未分化多形性肉瘤
肉瘤
彭布罗利珠单抗
软组织肉瘤
小梁
骨肉瘤
肿瘤科
异环磷酰胺
恶性肿瘤
化疗
内科学
脂肪肉瘤
病理
癌症
依托泊苷
免疫疗法
作者
Olivier Mir,Charles Honoré,Julien Adam
出处
期刊:Lancet Oncology
[Elsevier]
日期:2017-11-01
卷期号:18 (11): 1430-1431
被引量:6
标识
DOI:10.1016/s1470-2045(17)30685-x
摘要
Sarcoma is a highly heterogeneous malignancy (>50 histological subtypes), for which active treatments beyond doxorubicin and ifosfamide are restricted to only some histological subtypes. 1 ESMO/European Sarcoma Network Working GroupSoft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25: iii102-iii112 Summary Full Text Full Text PDF PubMed Scopus (483) Google Scholar Therefore, treatment selection in advanced disease is mainly based on histological subtype, although this approach has limitations in the perioperative setting. 2 Gronchi A Ferrari S Quagliuolo V et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18: 812-822 Summary Full Text Full Text PDF PubMed Scopus (292) Google Scholar Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialThe primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI